Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240029/S002

CGuard Prime Carotid Stent System

InspireMD, Ltd. · Decision date Mar 16, 2026

FDA DECISIONP240029/S002

What did the FDA decide?

FDA records P240029/S002 as a supplement to PMA P240029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 16, 2026.

FDA approval order statement

the introduction of an additional stent crimper
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Mar 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P240029/S002
Regulatory pathway
PMA supplement
Product code
NIM
Decision code
OK30
Decision date
Mar 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, carotid.

Product code
NIM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240029/S002 received

    Application receipt date recorded by FDA.

  2. P240029/S001 · Related supplement

    CGuard Prime Carotid Stent System

  3. P240029/S002 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240029

Product / regulatory recordCompanyPathwayDecision dateSource
InspireMD, Ltd.PMA supplementFeb 20, 2026FDA

Explore the linked device profile

Other records with product code NIM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

InspireMD, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6303 Waterford District Dr., Suite 215, Miami, FL, 33126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records